Needham & Company LLC Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)
Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $12.00 price objective on the stock. IMRX has been the topic of a number of other reports. Chardan Capital reiterated a “buy” rating and issued a […]
Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $12.00 price objective on the stock. IMRX has been the topic of a number of other reports. Chardan Capital reiterated a “buy” rating and issued a […]